Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08

Piper Jaffray says 'hard pressed' to see the logic behind Tesaro deal

Piper Jaffray analyst Christopher Raymond kept his Neutral rating and $35 price target on Tesaro, saying that today's Bloomberg report about the company exploring a sale in response to interest from potential buyers was a "headscratcher". The analyst notes that it is difficult to see the logic behind the deal given the headwinds faced by Zejula in the U.S. and in Europe. Raymond adds that the company's immuno-oncology portfolio "is still not ready for prime time" and that he would not be among the buyers of Tesaro stock.

  • 03

    Dec

TSRO Tesaro
$34.96

8.39 (31.58%)

10/22/18
CANT
10/22/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro price target raised to $68 from $57 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.
10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
11/09/18
PIPR
11/09/18
NO CHANGE
PIPR
Tesaro AMBER trial data incomplete, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond remained Neutral on Tesaro following what he calls "incomplete, if not disappointing" data for the company's AMBER trial evaluating anti-TIM-3 in combination with PD-1. That data, Raymond said, means waiting until 2019 for data from the higher dose arm. The analyst added that he has concerns on FY19 expectations for Tesaro's Zejula due to stagnating trends across the U.S. and the looming loss of full pricing in Germany next month, and is "comfortable remaining on the sidelines."
11/12/18
JEFF
11/12/18
NO CHANGE
Target $25
JEFF
Hold
Tesaro price target lowered to $25 from $38 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Tesaro to $25 saying the company's new immune-oncology data is "underwhelming." With slowing Zejula sales growth, Tesaro has been increasingly focused on I/O programs, Yang tells investors in a research note. She believes the company's data for new I/O therapy "fails to show meaningful additive effects when combined with its anti-PD-1." The analyst keeps a Hold rating on Tesaro.

TODAY'S FREE FLY STORIES

APC

Anadarko

$64.18

0.16 (0.25%)

, CVX

Chevron

$119.87

-0.38 (-0.32%)

06:20
04/22/19
04/22
06:20
04/22/19
06:20
Downgrade
Anadarko, Chevron rating change  »

Anadarko downgraded to…

APC

Anadarko

$64.18

0.16 (0.25%)

CVX

Chevron

$119.87

-0.38 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 30

    Apr

  • 14

    May

  • 22

    May

RTRX

Retrophin

$20.07

-0.13 (-0.64%)

06:18
04/22/19
04/22
06:18
04/22/19
06:18
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 08

    May

  • 05

    Jun

  • 30

    Jun

MU

Micron

$43.42

0.26 (0.60%)

06:18
04/22/19
04/22
06:18
04/22/19
06:18
Conference/Events
Micron management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

DTIL

Precision BioSciences

$12.15

-0.84 (-6.47%)

06:18
04/22/19
04/22
06:18
04/22/19
06:18
Initiation
Precision BioSciences initiated  »

Precision BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTRE

Watford Holdings

$28.24

0.5 (1.80%)

06:17
04/22/19
04/22
06:17
04/22/19
06:17
Initiation
Watford Holdings initiated  »

Watford Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$21.35

0.07 (0.33%)

06:15
04/22/19
04/22
06:15
04/22/19
06:15
Upgrade
Rent-A-Center rating change  »

Rent-A-Center upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENGIY

Engie SA

$0.00

(0.00%)

, EME

Emcor

$79.55

2.64 (3.43%)

06:15
04/22/19
04/22
06:15
04/22/19
06:15
Periodicals
France's Engie mulls takeover of Emcor, Bloomberg reports »

French energy firm Engie…

ENGIY

Engie SA

$0.00

(0.00%)

EME

Emcor

$79.55

2.64 (3.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAL

Caleres

$27.55

0.425 (1.57%)

06:14
04/22/19
04/22
06:14
04/22/19
06:14
Upgrade
Caleres rating change  »

Caleres upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOV

Dover

$97.93

1.12 (1.16%)

06:14
04/22/19
04/22
06:14
04/22/19
06:14
Downgrade
Dover rating change  »

Dover downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

TEVA

Teva

$14.36

0.14 (0.98%)

06:13
04/22/19
04/22
06:13
04/22/19
06:13
Hot Stocks
Teva receives FDA approval to market generic nasal spray for opioid overdoses »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

RCI

Rogers Communications

$51.39

-1.76 (-3.31%)

06:13
04/22/19
04/22
06:13
04/22/19
06:13
Downgrade
Rogers Communications rating change  »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 23

    May

TEVA

Teva

$14.36

0.14 (0.98%)

06:10
04/22/19
04/22
06:10
04/22/19
06:10
Hot Stocks
Teva receives FDA approval to market generic nasal spray for opioid overdoses »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

CAL

Caleres

$27.55

0.425 (1.57%)

06:09
04/22/19
04/22
06:09
04/22/19
06:09
Upgrade
Caleres rating change  »

Caleres upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$29.38

-1.37 (-4.46%)

06:08
04/22/19
04/22
06:08
04/22/19
06:08
Downgrade
Triumph Bancorp rating change  »

Triumph Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 16

    May

OKE

Oneok

06:08
04/22/19
04/22
06:08
04/22/19
06:08
Downgrade
Oneok rating change  »

Oneok downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 22

    May

MANH

Manhattan Associates

$57.31

0.18 (0.32%)

06:07
04/22/19
04/22
06:07
04/22/19
06:07
Upgrade
Manhattan Associates rating change  »

Manhattan Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 14

    May

NSANY

Nissan

$0.00

(0.00%)

06:07
04/22/19
04/22
06:07
04/22/19
06:07
Hot Stocks
Nissan says Nikkei output cut report 'completely incorrect' »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$86.75

1.26 (1.47%)

06:06
04/22/19
04/22
06:06
04/22/19
06:06
Downgrade
Autoliv rating change  »

Autoliv downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 23

    May

BXG

Bluegreen Vacations

$14.91

-0.43 (-2.80%)

06:06
04/22/19
04/22
06:06
04/22/19
06:06
Hot Stocks
Bass Pro to cancel access from Bluegreen Vacations »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.25

2.13 (0.79%)

06:06
04/22/19
04/22
06:06
04/22/19
06:06
Periodicals
Tesla probes incident of vehicle fire in Shanghai, CNBC reports »

Tesla immediately sent a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

BBBY

Bed Bath & Beyond

$17.43

0.14 (0.81%)

06:05
04/22/19
04/22
06:05
04/22/19
06:05
Hot Stocks
Bed Bath & Beyond forms Business Transformation and Strategy Review Committee »

The Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$23.75

0.285 (1.21%)

06:04
04/22/19
04/22
06:04
04/22/19
06:04
Periodicals
KKR, EQT potential biddres for Thomas Cook, Sky News reports »

Thomas Cook has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 11

    Jun

IPGP

IPG Photonics

06:04
04/22/19
04/22
06:04
04/22/19
06:04
Upgrade
IPG Photonics rating change  »

IPG Photonics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

SC

Santander Consumer

$22.54

-0.16 (-0.70%)

06:04
04/22/19
04/22
06:04
04/22/19
06:04
Downgrade
Santander Consumer rating change  »

Santander Consumer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

  • 24

    Jul

  • 30

    Oct

WASH

Washington Trust

$50.05

-0.06 (-0.12%)

06:04
04/22/19
04/22
06:04
04/22/19
06:04
Earnings
Washington Trust reports Q1 EPS $1.00, consensus 95c »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 23

    Apr

  • 13

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.